ICCM vs. APYX, HSAQ, AMIX, SEPA, SRTS, DXR, NSPR, CTSO, PDEX, and LUCD
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Apyx Medical (APYX), Health Sciences Acquisitions Co. 2 (HSAQ), Autonomix Medical (AMIX), SEP Acquisition (SEPA), Sensus Healthcare (SRTS), Daxor (DXR), InspireMD (NSPR), Cytosorbents (CTSO), Pro-Dex (PDEX), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
IceCure Medical (NASDAQ:ICCM) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
Apyx Medical received 60 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 94.44% of users gave IceCure Medical an outperform vote while only 61.60% of users gave Apyx Medical an outperform vote.
IceCure Medical currently has a consensus target price of $2.95, suggesting a potential upside of 152.14%. Apyx Medical has a consensus target price of $6.17, suggesting a potential upside of 271.49%. Given Apyx Medical's higher possible upside, analysts clearly believe Apyx Medical is more favorable than IceCure Medical.
IceCure Medical has higher earnings, but lower revenue than Apyx Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 55.3% of Apyx Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 13.1% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
IceCure Medical has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Apyx Medical has a net margin of -35.75% compared to IceCure Medical's net margin of -453.76%. Apyx Medical's return on equity of -54.90% beat IceCure Medical's return on equity.
In the previous week, Apyx Medical had 3 more articles in the media than IceCure Medical. MarketBeat recorded 5 mentions for Apyx Medical and 2 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.53 beat Apyx Medical's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.
Summary
Apyx Medical beats IceCure Medical on 11 of the 16 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
